Massachusetts is currently home to 3159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Early Intervention in High Risk CCUS
NCT06802146
Recruiting
This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment. The names of the study drug involved in this study is: -Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Clonal Cytopenia of Undetermined Significance, Cytopenia
Register for Updates
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
NCT06796686
Recruiting
This is a partially randomized, open-label phase 1 study to evaluate the safety and immunogenicity of a priming regimen of 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum followed by boosts with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum. The primary hypothesis is that the boosting with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum will further mature broadly neutralizing antibody (bnAb)-precursor B-cell lineages elicited by 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum. 426... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/24/2025
Locations: Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts
Conditions: HIV
Register for Updates
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250
Recruiting
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Research Site, Boston, Massachusetts
Conditions: B-cell Malignancies
Register for Updates
Advanced Imaging for Pulmonary Fibrosis
NCT06532071
Recruiting
The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Fibrosis
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis
Register for Updates
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
NCT06328127
Recruiting
This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Hematopoietic Stem Cell Transplant
Register for Updates
Revumenib in Combination With 7+3 + Midostaurin in AML
NCT06313437
Recruiting
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Re... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Register for Updates
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
NCT06296394
Recruiting
The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the impact of parenthood in CF with widespread highly effective CFTR modulator use. The main hypotheses this study aims to examine are: H1: Parents with CF and moderate-to-severe depression have more rapid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis, Parenthood Status
Register for Updates
TRIcvalve BiCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807
Recruiting
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Register for Updates
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
03/24/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Choosing Wisely: De-implementing Fall Prevention Alarms in Hospitals
NCT06089239
Recruiting
This is a Hybrid II de-implementation study to reduce use of fall prevention alarms in hospitals. The intervention consists of tailored, site-specific approaches for three core implementation strategies: education, audit/feedback and opinion leaders. Hospital units will be randomized to low-intensity or high-intensity coaching for the implementation of the tailored strategies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: UMass Memorial Health Harrington, Southbridge, Massachusetts
Conditions: Accidental Fall, Patient Safety, Hospital Acquired Condition, Clinical Alarms, Mentoring
Register for Updates
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
NCT05855083
Recruiting
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
Gender:
ALL
Ages:
Between 28 days and 17 years
Trial Updated:
03/24/2025
Locations: Omeros Investigational Site, Boston, Massachusetts
Conditions: Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Register for Updates